UX Data Sciences acquired by ChroMedX

24 May 2018
Client work


On May 24, 2018, ChroMedX Corp. (CSE: CHX) (OTC: CHXIF) (Frankfurt: EIY2) announced the closing of its previously announced acquisition of UX Data Sciences Corp. ("UXD"). ChroMedX issued common shares valued at $5.5 million to the shareholders of UXD. With this transaction, UXD became a wholly-owned subsidiary of ChroMedX. 

ChroMedX Corp. is a medical technology company focused on the development of novel, handheld medical devices for diagnostic testing. UXD is an Ottawa, Ontario-based medical technology and data science company developing products and systems solutions for improving, tracking and monitoring patient compliance and medication adherence.

Gowling WLG advised UXD in this transaction with a team that included Garrett Hamel and Lorraine Mastersmith (corporate and securities).

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.
Related   Mergers & Acquisitions, Corporate Commercial

Related Insights & Resources

View all insights Related Insights & Resources
Client work
10 May 2021 PlantX completes acquisition of US-based Little West LLC
Articles
05 May 2021 Modern slavery: Conducting supply chain risk assessment and due diligence
Client work
29 April 2021 Leading Edge Materials completes sale of Bergby Lithium Project in Sweden

Team

Download or print PDF